Aridis Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track designation to Aerucin for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Aerucin is a broadly reactive fully human immunoglobulin G (IgG), mAb targeting P. aeruginosa bacteria that exhibits broad binding to greater than 90% of clinical isolates of P. aeruginosa.

RELATED: Narrow-Spectrum Antibiotic Use for CAP Up After Guideline Implementation

Aerucin is currently under evaluation in a Phase 1 clinical trial to determine its safety and pharmacokinetics in healthy adults. Results are expected to be complete in the fourth quarter of this year.

For more information visit